Elevated polyreactive immunoglobulin G in immune mediated liver injuries with the need for immunosuppressive therapy

Competing Interest Statement

Richard Taubert and Elmar Jaeckel are inventors of the patent application for the use of anti-HIP1R/BSA for the diagnosis of AIH (granted patent: EP3701264 B1; running patent application: 16/754,006). EUROIMMUN Medizinische Labordiagnostika AG and Inova Diagnostics Inc. provided ELISAs free of charge for other projects of Richard Taubert and Bastian Engel. Ye H Oo thanks the Sir Jules Thorn Charitable Trust and Whitney Wood Fellowship. All other authors have nothing to disclose with regard to this paper.

Funding Statement

Bastian Engel was supported by the PRACTIS Clinician Scientist Programme of Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Written informed consent was obtained from all patients at respective centers. Use of material and data from all patients in this multicenter study was approved by the respective local ethical committees. The study was approved by the local Ethics Committee (Number 5582 with last Update from 2018, Hannover Medical School Ethics Committee, Hannover Medical School, Hannover, Germany). The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes